Epizyme, Inc. is a fully integrated biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through transformative epigenetic medicines. In addition to a robust research and discovery pipeline, Epizyme has one commercial oncology product and is exploring the treatment potential of this therapy in investigational clinical trials focused on other conditions. By focusing on the genetic drivers of disease, Epizyme works to match new medicines with the patients who need them. For more information, visit www.epizyme.com.
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our employees around the world are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. We currently market an internally discovered product in the United States, BRUKINSA® (zanubrutinib).
Kyowa Kirin is a global specialty pharmaceutical company with US Headquarters based in Bedminster, NJ. The company is focused primarily on developing and commercializing biopharmaceuticals that help improve the health and well-being of people through innovative and state-of-the-art technologies in various therapeutic areas including oncology, neurology, nephrology, and immunology. For additional information, you can visit us at www.kyowakirin.com.
EUSA Pharma is a dynamic, global biopharmaceutical company focused on oncology and rare disease, continuously striving to confront gaps in patient care. Our ambition drives us to deliver medical treatments that deliver real change to improve lives wherever they are needed in the world. As a young, specialty pharmaceutical company, EUSA Pharma is committed to delivering solutions that can have a meaningful effect on life, helping patients across a range of therapy areas.
The global oncology business unit of Takeda Pharmaceutical possesses a passion for improving patients’ lives, rooted in a strong heritage of science and innovation. We are changing expectations in science by focusing on treatments that address forms of cancer that haven’t traditionally been the focus of oncology R&D. This emphasis on cutting-edge science informs all aspects of our strategy, from early-stage research and clinical programs to our business development and collaboration approach.
Takeda’s proven commercialization capabilities allow us to quickly respond to the diverse and dynamic needs of patients, healthcare providers and health systems globally. We are a force of more than 2,000 dedicated oncology professionals, driven by a patient-focused entrepreneurial spirit and commitment to agility, even as our organization grows. We continually look for opportunities to collaborate with innovative and forward-thinking companies to quickly bring transformative therapies to market.
Finally, we’re changing expectations about what it means to partner with patients. We’ve redefined patient advocacy relations and our team cares about patients in a way that influences every decision we make. Understanding their journeys challenges us to continually bring better medicines to market.
Every day, we come to work committed to changing expectations through our relentless pursuit of game-changing science, forging the right partnerships and learning from successes and failures. We will continue to redefine paradigms and create a profound impact on patients’ lives. Our vision will not be achieved quickly or simply, but we are up to the task: We Aspire to Cure Cancer.